Cancer vaccines

John T. Schiller; Douglas R. Lowy; Ian H. Frazer; Olivera J. Finn; Eduardo Vilar; H. Kim Lyerly; Sacha Gnjatic; Neeha Zaidi; Patrick A. Ott; Vinod P. Balachandran; Pierre Yves Dietrich; Denis Migliorini; Robert H. Vonderheide; Susan M. Domchek

doi:10.1016/j.ccell.2022.05.015

Cancer vaccines

John T. Schiller, Douglas R. Lowy, Ian H. Frazer, Olivera J. Finn, Eduardo Vilar, H. Kim Lyerly, Sacha Gnjatic, Neeha Zaidi, Patrick A. Ott, Vinod P. Balachandran, Pierre Yves Dietrich, Denis Migliorini, Robert H. Vonderheide, Susan M. Domchek

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.

Original language	English (US)
Pages (from-to)	559-564
Number of pages	6
Journal	Cancer cell
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2022.05.015
State	Published - Jun 13 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2022.05.015

Cite this

@article{eb6d368969fc4cdc81a2562cc657569d,

title = "Cancer vaccines",

abstract = "Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.",

author = "Schiller, {John T.} and Lowy, {Douglas R.} and Frazer, {Ian H.} and Finn, {Olivera J.} and Eduardo Vilar and Lyerly, {H. Kim} and Sacha Gnjatic and Neeha Zaidi and Ott, {Patrick A.} and Balachandran, {Vinod P.} and Dietrich, {Pierre Yves} and Denis Migliorini and Vonderheide, {Robert H.} and Domchek, {Susan M.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jun,

day = "13",

doi = "10.1016/j.ccell.2022.05.015",

language = "English (US)",

volume = "40",

pages = "559--564",

journal = "Cancer cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Cancer vaccines

AU - Schiller, John T.

AU - Lowy, Douglas R.

AU - Frazer, Ian H.

AU - Finn, Olivera J.

AU - Vilar, Eduardo

AU - Lyerly, H. Kim

AU - Gnjatic, Sacha

AU - Zaidi, Neeha

AU - Ott, Patrick A.

AU - Balachandran, Vinod P.

AU - Dietrich, Pierre Yves

AU - Migliorini, Denis

AU - Vonderheide, Robert H.

AU - Domchek, Susan M.

PY - 2022/6/13

Y1 - 2022/6/13

N2 - Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.

AB - Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for their broad implementation.

UR - http://www.scopus.com/inward/record.url?scp=85131588322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131588322&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.05.015

DO - 10.1016/j.ccell.2022.05.015

M3 - Comment/debate

C2 - 35700704

AN - SCOPUS:85131588322

SN - 1535-6108

VL - 40

SP - 559

EP - 564

JO - Cancer cell

JF - Cancer cell

IS - 6

ER -

Cancer vaccines

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this